In a report released today, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Bicara Therapeutics Inc. (BCAX – Research Report).

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient ...

From January 13 to 16, Dr. Huiming Li, Deputy General Manager of Kexing Biopharm New Drug Research Center, attended the 17th Biotech Showcase conference in San Francisco and the Global Biopharma ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that on January 21, 2025, it granted stock options to purchase an ...

Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced that Pankaj Mohan, Ph.D., Chief ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

The "Home Care Testing Market Size, Share & Trends Analysis Report By Age, By Sample, By Test Type, By Distribution Channel, ...

New Activin R-based medications can emerge as perfect solutions for balancing weight loss and muscle building, making a ...

AbCellera Biologics Inc. (ABCL)'s share was trading at $2.94 as of Jan 16 th. ABCL’s trailing P/E was 19.92 according to ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

(Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company developing new therapeutic pathways for metabolic health, enters 2025 positioned to announce Phase 2 data for nimacimab, a ...

Antibodies that bind to a previously untargeted portion of the malaria parasite could lead to new monoclonal antibody treatments and vaccines for malaria. A novel class of antibodies that binds to ...